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maintenance treatment with thiopurine. This could be in-
ferred from the fact that other maintenance treatments such 
as biologics should be considered in refractory UC patients 
treated with high-dose corticosteroids. 
Mucosal healing (MH) is becoming more widely ac-
cepted as a relevant outcome marker for UC. In a Norwegian 
population-based cohort study examining effects between 
the presence or absence of MH and long-term outcomes, 
MH at 1 year was confirmed in 50% of UC patients, and the 
colectomy rate at 5 years was 1.7%. MH at 1 year significantly 
decreased the need for colectomy at 5 years,4 and this as-
sociation was significant after adjusting for factors that may 
influence colectomy, such as age, smoking, education level, 
and disease extent. Therefore, the previous study provides 
evidence that MH is strongly associated with the clinical 
outcomes of UC. Yamada et al. reported MH rates of >60% at 
26.8 months, and a colectomy rate of 3.6%. Compared to that 
of Western studies, this result was not significantly different. 
However, only two-thirds of study patients underwent colo-
noscopy to evaluate MH and the time interval between initi-
ating thiopurine therapy and performing the colonoscopy to 
assess MH was different in each patient due to the retrospec-
tive design of the study. Therefore, the results of Yamada et 
al. should be interpreted while considering the limitations of 
the study, such as the small number of patients included and 
the lack of adjustment for potential confounding factors. 
Efficacy must be balanced against safety and tolerability. In 
the Yamada et al. study, the median dose of thiopurine was 
50 mg. Traditionally, the dose-escalating approach is used in 
The thiopurines, azathioprine and 6-mercaptopurine, have 
been in clinical use for 50 years. Prospective studies and 
meta-analyses suggest that thiopurines are effective for the 
maintenance of remission in UC.1,2 By maintaining remis-
sion, hospitalization and colectomy rates can be reduced, 
and long-term complications prevented. However, in the 
biologic era, the long-term efficacy of thiopurine needs to be 
better understood.
In this issue of Intestinal Research, Yamada et al. tried to 
assess the long-term efficacy and safety of maintenance 
treatment with thiopurines in UC.3 They enrolled a total of 
59 bio-naive patients who maintained remission by treat-
ment with thiopurine and 5-aminosalicylate after induction. 
The cumulative remission-maintenance rates at 24, 48, and 
84 months were reported as approximately 69%, 55%, and 
44%, respectively. Recent meta-analyses of trial data revealed 
remission maintenance rates of 56−76% during thiopurine 
treatment.1,2 The remission maintenance rate of Yamada 
et al. was similar to that of meta-analyses, considering that 
the mean follow-up period of these studies was shorter. Ya-
mada et al. also demonstrated that high-dose corticosteroid 
treatment (≥40 mg/day) was a negative predictive factor for 
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East Asian patients.5,6 Several trials, including this study, have 
suggested that lower doses of azathioprine or 6-mercap-
topurine may be effective and safe for the treatment of UC 
patients,7,8 contrary to the results of Western studies. Accord-
ing to previous studies, approximately 10−28% of patients 
reported adverse events (AEs), and 25.6% of patients had to 
discontinue thiopurine therapy due to AEs.9,10 A similar rate 
of AEs (28.8%) was reported in the study by Yamada et al. In 
this study, the discontinuation rate due to AEs was reported 
as low as 10.2%, probably due to low thiopurine dose they 
used. Although there were no severe AEs such as lymphoma 
and non-melanoma skin cancer in the Yamada et al. study, 
and the absolute risks of these malignancies remain low, 
the risks and benefits of continuing or ceasing thiopurine 
therapy should be weighed for each individual patient.   
Despite the fact that clinical trials (including the Yamada 
et al. study) concerning the use of thiopurines for UC have 
been heterogeneous in design, the evidence is sufficient to 
conclude that thiopurines are effective for maintenance of 
remission. 
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